Articles

Phase 2 study results of second-line trastuzumab deruxtecan use in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer revealed an antitumor response. Read More ›

Researchers reported that molecular testing in patients with non–small-cell lung cancer aged ≥70 years is performed at the same proportions as in younger patients. Read More ›

Analysis of EGFR, KRAS, and PIK3CA gene mutation rates in patients with lung cancer revealed a correlation with clinical characteristics that may have a significant effect on personalized cancer treatment. Read More ›

A recently released report indicates that low-dose computed tomography targeted screening for lung cancer confers patient health and public health benefits. Read More ›

A large cohort analysis of treatment status, treatment regimen, and outcomes in patients with KRAS-mutated advanced NSCLC revealed valuable information for future clinical trials. Read More ›

The Stanford Cancer Center is widely known for its advanced clinical care, scientific research, and surgical innovations, and is consistently recognized as one of the top hospitals in America for cancer care by US News & World Report. Read More ›

Biosimilars have the potential to create a more sustainable healthcare environment by offering substantial cost-savings and expanding patient access to lifesaving therapies. Read More ›

Medicaid expansion under the Affordable Care Act was associated with significant increases in breast reconstruction surgery among non-Hispanic black women and women with lower income and education levels, according to results of a study presented during the American Society of Breast Surgeons 22nd Annual Meeting. Read More ›

Treatment with the checkpoint inhibitor pembrolizumab (Keytruda) following surgery significantly extended disease-free survival (DFS) in patients with high-risk, clear-cell renal-cell carcinoma (RCC) compared with placebo, according to the results of the KEYNOTE-564 clinical trial. These findings were reported during a plenary session of the American Society of Clinical Oncology (ASCO) 2021 virtual annual meeting. Read More ›